<DOC>
	<DOCNO>NCT01535885</DOCNO>
	<brief_summary>This protocol phase I study . Patients may eligible infusion Multi-virus Cytotoxic T Lymphocytes ( CTL ) receive T-cell deplete ( TCD ) transplant relate family member unrelated donor . Recipients type transplant severely immune compromise early post-transplant period susceptible certain virus . The investigator hypothesize adoptive transfer Cytotoxic T Lymphocytes ( CTL ) certain virus : Adenovirus , Cytomegalovirus Epstein Barr Virus ( Ad , CMV , EBV ) safe regard produce graft versus host disease ( GVHD ) infusion relate toxicity .</brief_summary>
	<brief_title>Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT Prophylaxis Against Epstein Barr Virus , Adenovirus , And Cytomegalovirus</brief_title>
	<detailed_description>Within clinical trial , investigator test hypothesis administration CTLs prophylaxis Ad , CMV EBV recipients TCD-HPCT safe well tolerate . Graded dose Multi-Virus CTL administer recipient genotypically haploidentical mismatch unrelated TCD graft .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Epstein-Barr Virus Infections</mesh_term>
	<criteria>Patient age &lt; 22 year . Both gender race eligible . The patient population choose Tcell deplete allogeneic HPCT relate unrelated allogeneic donor must meet eligibility base institutional SOPs and/or IRB approve T cell deplete allogeneic HPCT protocol enrol . Must willing sign write informed consent . Patient Organ Status time enrollment ( pretransplant ) Lansky Karnofsky score &gt; 50 Echocardiogram shorten fraction &gt; 27 % Renal function : serum creatinine &lt; 2 x normal age DLCO &gt; 50 % predict patient old enough comply PFTs baseline oxygen requirement young patient . Hepatic : AST , ALT &lt; 5x upper limit normal ; bilirubin &lt; 2.0 mg/dl Sexually active patient must willing utilize one effective birth control method 6 month follow CTL infusion . The male partner use condom . Patients must 28 100 day post Tcell deplete allogeneic HPCT Patients must meet follow criterion ( within 72 hour CTL infusion ) : Achieved primary engraftment ANC least 1000 per Î¼l 3 consecutive day . No oxygen requirement oxygen saturation &gt; 90 % . AST , ALT &lt; 5x upper limit normal age ; bilirubin &lt; 2 mg/dl . Hemoglobin &gt; 8 gm/dl prior infusion . ( May transfusion dependent ) . Renal function : serum creatinine &lt; 2 x normal age . The Patient must follow condition day CTL infusion : Exhibit overt hematologic manifestation relapse persistent disease . Evidence recurrent/persistent disease base primarily flow cytometry , cytogenetics , chimerism analysis , molecular study represent ground exclusion . Currently enrol another Phase I clinical trial . Pregnant nursing Overt hematologic manifestation relapse persistent disease Having &gt; grade 1 graftversushost disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cytoxic T Lymphocytes ( CTL )</keyword>
	<keyword>T-cell Depleted</keyword>
	<keyword>Allogeneic Transplant</keyword>
	<keyword>Epstein Barr Virus</keyword>
	<keyword>Adenovirus</keyword>
	<keyword>Cytomegalovirus</keyword>
	<keyword>Hematopoietic progenitor cell transplantation</keyword>
</DOC>